RU2005128284A - Продленные режимы чрескожной контрацепции - Google Patents
Продленные режимы чрескожной контрацепции Download PDFInfo
- Publication number
- RU2005128284A RU2005128284A RU2005128284/14A RU2005128284A RU2005128284A RU 2005128284 A RU2005128284 A RU 2005128284A RU 2005128284/14 A RU2005128284/14 A RU 2005128284/14A RU 2005128284 A RU2005128284 A RU 2005128284A RU 2005128284 A RU2005128284 A RU 2005128284A
- Authority
- RU
- Russia
- Prior art keywords
- contraceptive
- therapy
- ethinyl estradiol
- unit
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Claims (8)
1. Способ контрацепции, включающей стадии введения женщине, имеющей менструации, цикла контрацептивной терапии, где каждый цикл терапии включает чрескожное введение комбинации этинилэстрадиола и норелгестромина в течение по меньшей мере 42 последовательных дней, где указанный способ обеспечивает улучшенное регулирование кровотечения и улучшенную величину продолжительности удовлетворительного состояния у женщин, имеющих менструации, использующих указанный способ.
2. Способ по п.1, где каждый цикл терапии включает 56 последовательных дня терапии.
3. Способ по п.2, где каждый цикл включает период без введения гормона, последующий за 56 днями непрерывной терапии.
4. Способ по п.3, где период без введения гормона составляет от 4-8 дней.
5. Способ по п.1, где 20 мкг этинилэстрадиола и 150 мкг норелгестромина вводится ежедневно.
6. Контрацептивная терапевтическая единица, предназначенная для введения при продленном контрацептивном режиме, где указанная единица содержит достаточное количество чрескожных пластырей для обеспечения по меньшей мере 42 последовательных дня контрацептивной терапии, где каждый чрескожный пластырь включает соответствующую матрицу и комбинацию этинилэстрадиола и норелгестромина, и где указанный режим обеспечивает улучшенное регулирование кровотечения и улучшенную величину продолжительности удовлетворительного состояния у женщин, имеющих менструации, использующих указанный режим.
7. Единица по п.6, где указанная единица включает 8 чрескожных пластырей.
8. Единица по п.4, где каждый пластырь обеспечивает ежедневное введение 20 мкг этинилэстрадиола и 150 мкг норелгестромина.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/385,597 | 2003-03-11 | ||
| US10/385,597 US20030219471A1 (en) | 2002-03-11 | 2003-03-11 | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005128284A true RU2005128284A (ru) | 2006-02-10 |
Family
ID=32987305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005128284/14A RU2005128284A (ru) | 2003-03-11 | 2003-07-24 | Продленные режимы чрескожной контрацепции |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030219471A1 (ru) |
| EP (1) | EP1613293A1 (ru) |
| KR (1) | KR20070006543A (ru) |
| CN (1) | CN1771024A (ru) |
| AU (1) | AU2003252139A1 (ru) |
| BR (1) | BR0318192A (ru) |
| CA (1) | CA2517778A1 (ru) |
| CR (1) | CR8010A (ru) |
| EC (1) | ECSP056009A (ru) |
| MX (1) | MXPA05009656A (ru) |
| RU (1) | RU2005128284A (ru) |
| WO (1) | WO2004080442A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| EP1453521B1 (en) | 2001-12-05 | 2013-09-04 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| EP1624848A4 (en) | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE |
| US7816546B2 (en) * | 2003-06-30 | 2010-10-19 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime |
| NZ585546A (en) | 2003-07-16 | 2011-10-28 | Teva Womens Health Inc | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| EP2392332A1 (en) * | 2004-10-07 | 2011-12-07 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| ES2558030T3 (es) * | 2006-03-02 | 2016-02-01 | Warner Chilcott Company, Llc | Método anticonceptivo oral multifásico de ciclo prolongado |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3545397A (en) * | 1969-03-17 | 1970-12-08 | Dowty Technical Dev Ltd | Air-cushion vehicles and like craft |
| IL48277A (en) * | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
| US4292965A (en) * | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
| US5188835A (en) * | 1986-06-16 | 1993-02-23 | Kabi Pharmacia Ab | Intravaginal devices |
| SE8602666D0 (sv) * | 1986-06-16 | 1986-06-16 | Leo Ab | Intravaginal devices |
| US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
| US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| DE4344463A1 (de) * | 1993-12-22 | 1995-06-29 | Schering Ag | Kombinationsprodukt zur Kontrazeption |
| RU2177311C2 (ru) * | 1995-06-07 | 2001-12-27 | Орто-Макнейл Фармасьютикалз Инк. | Трансдермальный пластырь для введения 17-деацетилноргестимата отдельно или в сочетании с эстрогеном |
| WO2003077926A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
-
2003
- 2003-03-11 US US10/385,597 patent/US20030219471A1/en not_active Abandoned
- 2003-07-24 CN CNA038264390A patent/CN1771024A/zh active Pending
- 2003-07-24 WO PCT/US2003/023134 patent/WO2004080442A1/en not_active Application Discontinuation
- 2003-07-24 KR KR1020057016954A patent/KR20070006543A/ko not_active Application Discontinuation
- 2003-07-24 BR BRPI0318192-8A patent/BR0318192A/pt not_active IP Right Cessation
- 2003-07-24 MX MXPA05009656A patent/MXPA05009656A/es unknown
- 2003-07-24 CA CA002517778A patent/CA2517778A1/en not_active Abandoned
- 2003-07-24 EP EP03816278A patent/EP1613293A1/en not_active Withdrawn
- 2003-07-24 AU AU2003252139A patent/AU2003252139A1/en not_active Abandoned
- 2003-07-24 RU RU2005128284/14A patent/RU2005128284A/ru not_active Application Discontinuation
-
2005
- 2005-09-08 EC EC2005006009A patent/ECSP056009A/es unknown
- 2005-09-28 CR CR8010A patent/CR8010A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05009656A (es) | 2006-03-08 |
| CA2517778A1 (en) | 2004-09-23 |
| US20030219471A1 (en) | 2003-11-27 |
| CR8010A (es) | 2009-01-16 |
| WO2004080442A1 (en) | 2004-09-23 |
| EP1613293A1 (en) | 2006-01-11 |
| ECSP056009A (es) | 2006-07-28 |
| CN1771024A (zh) | 2006-05-10 |
| KR20070006543A (ko) | 2007-01-11 |
| AU2003252139A1 (en) | 2004-09-30 |
| BR0318192A (pt) | 2006-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL323729A1 (en) | Skin sticking plaster and method of administering sole 17-deacetyl norgestimate or together with estrogen | |
| US5422119A (en) | Transdermal hormone replacement therapy | |
| CA2624810A1 (en) | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith | |
| NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
| RU2000112650A (ru) | Прогестинотерапия с регулируемым кровотечением | |
| NO986104D0 (no) | Progesteron-anti-progesteron regimer | |
| JP2005516913A5 (ru) | ||
| HUP9904344A2 (hu) | Egyfázisú fogamzásgátló eljárás és progesztin és ösztrogén kombinációját tartalmazó kit | |
| RU2005128284A (ru) | Продленные режимы чрескожной контрацепции | |
| US20070077269A1 (en) | Method of birth control and hormone regulation | |
| KR20000029536A (ko) | 2상피임방법및프로제스틴과에스트로젠과의배합물을포함하는킷 | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| RU2006145077A (ru) | Применение комбинации из этинилэстрадиола и ацетата хлормадинона для приготовления лекарственного средства | |
| Youngkin | Estrogen replacement therapy and the estraderm transdermal system | |
| CN2229266Y (zh) | 治疗乳腺增生的外用贴剂 | |
| JP2000514441A (ja) | 月経前症候群の１又は複数の症状を抑制するための医薬組成物の製造のための３，４―ジフェニルクロマンの使用 | |
| RU2001131730A (ru) | Применение антипрогестогенов в комбинированной терапии | |
| DK1937274T3 (da) | Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception | |
| Radowicki et al. | CYCLE CONTROL DURING THE TREATMENT OF A TRANSDERMAL CONTRACEPTIVE SYSTEM | |
| DAVIS | Estrogenic therapy in gynecology | |
| WO1994014450A1 (en) | Transdermal, multiphasic hormone replacement therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080610 |